MELVILLE, N.Y.--(BUSINESS WIRE)--Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced the Company has received 510(k) clearance from the Food and Drug Administration (FDA) to market its J-Plasma ICON GS electrosurgical generator and handpiece.
The technology utilizes a gas ionization process producing a stable thin focused beam of ionized helium gas that can be controlled in a wide range of temperatures and intensities, providing the surgeon greater precision, minimal invasiveness and an absence of conductive currents during surgery. Independent control of the beam power (heating) and helium flow rate (cooling) produces a highly localized effect with minimal collateral damage to the surrounding healthy tissue.
Management believes the J-Plasma technology has a wide variety of medical applications including dermatology, gynecology, hepatobiliary (liver), thoracic and general surgery. The Company is consulting with both domestic and international physicians and scientists experienced in the field of plasma medicine to accelerate the commercialization of the technology in the U.S. and abroad. Worldwide revenues for the targeted surgical procedures are estimated to exceed $2 billion.
Mr. David Uffer, vice president of advanced technologies and director of plasma sales and marketing will lead the Company’s efforts in developing the technology’s applications and commercialization.
Andrew Makrides, president of Bovie Medical stated, “Management remains very encouraged regarding the potential of the J-Plasma technology. The FDA clearance to market J-Plasma is a milestone in our continued evolution into a high-tech medical device company.”
For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.
This document may contain some forward looking statements, particularly regarding operational prospects in 2009 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings.
Contact:
Investor: Buttonwood Advisory Group, Inc. John Aneralla, 1-800-940-9087
